Carol Gallagher, Pharm.D.
An industry veteran with more than 25 years of experience in commercial, drug development and business development roles at large and small biopharmaceutical companies, Dr. Gallagher is a partner with New Enterprise Associates, Inc. (NEA). In addition to her role at NEA, Dr. Gallagher is the chairman of Atara Biotherapeutics and AnaptysBio. She previously served as the chairman of eFFECTOR Therapeutics, a director at Aragon Pharmaceuticals (acquired by Johnson & Johnson in 2013), and a venture partner with Frazier Healthcare. Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals, where she raised $80 million in venture financing and advanced the company's lead molecule, CAL-101, into full development, securing a successful exit with the $600 million acquisition by Gilead Sciences in April 2011. Dr. Gallagher began her career in sales and marketing at Eli Lilly in 1989 and also held various commercial and development roles at Amgen, Agouron Pharmaceuticals, Pfizer, CancerVax and Anadys. Notable during her career was her role as the Rituxan Development Team Leader at Idec Pharmaceuticals and after the merger, Biogen Idec.
Dr. Gallagher attended Vanderbilt University and holds B.S. and Pharm.D. degrees from the College of Pharmacy at the University of Kentucky.
Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley has served as President and as a member of the board of directors of TESARO, Inc. since co-founding the company in March 2010. Prior to TESARO, Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience, a biotechnology company. Dr. Hedley previously served as Executive Vice President of Eisai Corporation of North America following the company's acquisition of MGI Pharma in January 2008. Prior to its acquisition by Eisai, Dr. Hedley served in various positions at MGI Pharma, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and served as the President and Chief Executive Officer of Zycos, a biotechnology company which was acquired by MGI Pharma in 2004.
Dr. Hedley earned her Ph.D. in immunology from the University of Texas, Southwestern Medical Center and her B.S. in microbiology from Purdue University. Her postdoctoral training included two consecutive postdoctoral fellowships at Harvard University. She currently serves on the Board of Directors of Youville Place, an assisted living facility, and previously served on the Board of Directors of Receptos until its acquisition by Celgene.
Mr. James Hindman has over 30 years of global and strategic senior financial experience in the pharmaceutical, biologics, and medical device industries. He enjoyed a long and esteemed career with Allergan, Inc., starting with the company as Manager of Accounting in 1984 and most recently serving as Executive Vice President of Finance and Business Development and Chief Financial Officer. Under his leadership, Allergan achieved its most robust financial performance in the company’s 64-year history. Mr. Hindman was instrumental in facilitating the largest restructuring and rewiring of Allergan, creating $20B in shareholder value that ultimately led to Actavis’ acquisition of Allergan in 2015 and the creation of one of the top ten global pharmaceutical firms. During his 30-year tenure at Allergan, Mr. Hindman held various senior leadership positions including Executive Vice President of Finance and Business Development and Chief Financial Officer, and Senior Vice President, Finance and Controller, and was responsible for strategic and financial functions including treasury, investor relations, risk, controller, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009-2015.
Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves as Director of NeuroSigma, Inc. and is a member of the Loyola Marymount University Board of Trustees.
John Howe, III, M.D.
Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. He was a member of the board of directors of OvaScience, Inc. from June 2015 until the closing of Millendo’s merger with OvaScience in December 2018. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe's tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the health education and life improvement of women and children. Before Project HOPE, Dr. Howe held the Distinguished Chair in Health Policy at The University of Texas Health Science Center at San Antonio; he served as the Center's chief executive from 1985 through 2000 and is currently the President Emeritus.
Dr. Howe is a board member of BB&T Bank, the Chinese Center for Communicable Disease Control and Prevention, the John E. Fogarty International Center at the National Institutes of Health and the Texas Biomedical Research Institute, among others. Among Dr. Howe's numerous honors and awards are the U.S. Army's Commander's Award for Public Service, the Surgeon General's Exemplary Service Award, and the Magnolia Award from the City of Shanghai, China. Dr. Howe is a published author of numerous articles, chapters and abstracts in medical journals, including the New England Journal of Medicine and the Annals of Internal Medicine, among others. Dr. Howe holds a B.A. from Amherst College and an M.D. from Boston University School of Medicine.
Carole Nuechterlein, J.D.
Ms. Carole Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2001 and currently serves as Head of the Roche Venture Fund. Previously, Ms. Nuechterlein served as General Counsel for SangStat, Inc. She began her career in the mergers and acquisitions group at Skadden Arps Slate Meagher & Flom.
Ms. Nuechterlein earned her B.A. from Valparaiso University and J.D. from the University of Michigan. She currently serves on the board of directors for AveXis, CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Mission Therapeutics, Second Genome, and Tioma Therapeutics and as an observer at Allakos and MacuLogix. Her previous investment and board experience includes Alios BioPharma, Ambit Biosciences, Envoy Therapeutics and Pharmasset.
Julia C. Owens, Ph.D.
Dr. Julia C. Owens co-founded Millendo Therapeutics in 2012 and has served as President and Chief Executive Officer since its inception. Dr. Owens has an extensive track record of building successful biopharmaceutical companies, with particular expertise in business development, strategic partnerships and mergers and acquisitions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that culminated in a major research partnership with Merck & Co. and the acquisition of a new platform discovery program for the company. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals where she established key strategic partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) where she led partnering for oncology and immunology as well as technology acquisition efforts, after beginning her biotech business career at the University of California, San Francisco Office of Technology Management.
Dr. Owens serves on the Board of Directors for the Biotechnology Innovation Organization (BIO) and its Emerging Companies Section Governing Board, the Leadership Council for the Life Sciences Institute at the University of Michigan, the Investment Advisory Board for the U-M Monroe-Brown Seed Fund and the Millendo Therapeutics Board of Directors.
Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.
Randall Whitcomb, M.D.
Dr. Randy Whitcomb has over 35 years of experience as an endocrinologist, chief medical officer, and drug development executive. He is a Senior Advisor to Frazier Healthcare Partners' Life Sciences team and is closely involved with the sourcing and evaluation of new opportunities. He has been involved with a number of portfolio companies to assist with clinical trial design and execution, regulatory strategy, and other development-related activities.
Previously, Dr. Whitcomb was a co-founder and Chief Medical Officer of QuatRx Pharmaceuticals, a pharmaceutical company focusing on compounds in the endocrine and metabolic therapeutic areas. Earlier he served in various management positions at Parke-Davis, the pharmaceutical division of Warner-Lambert, including VP for Clinical Research and Drug Development. After Pfizer acquired Warner-Lambert, Dr. Whitcomb was VP of Global Project Management for Pfizer. Throughout his time in the pharmaceutical industry, he has been involved in the development and approval of several drugs including: Lipitor, Rezulin, FemHRT, Estrostep, and Osphena. Prior to his tenure at Parke-Davis, Dr. Whitcomb was on the faculty of the Harvard Medical School and an attending physician at Massachusetts General Hospital. He previously served on the boards of Insmed, Inc. and Marcadia Biotech, Inc.
Dr. Whitcomb received his M.D. from the University of Kansas, where he did clinical training in internal medicine and endocrinology followed by a research fellowship at N.I.H. He earned a B.A. in Biology and Chemistry from Tabor College. Randy has authored multiple scientific publications and is a member of numerous scientific and clinical organizations.
Mr. Dable has served as the President and Chief Executive Officer of Acceleron Pharma since 2016. Prior to joining Acceleron, he spent more than 20 years at Bayer AG in a number of commercial and operational leadership roles, ending his tenure there as President of Pharmaceuticals in the U.S. In this role, he was responsible for several new product launches while managing Bayer AG’s multi-billion-dollar portfolio spanning therapeutic areas including hematology, neurology, oncology, women's health, and cardiovascular disease. Prior to his role as President of U.S. Pharmaceuticals at Bayer AG, Mr. Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, where he was responsible for the global launch of multiple blockbuster brands, including EYLEA®, Stivarga® and Xofigo®. Mr. Dable recently served on the board of directors of the Biotechnology Innovation Organization (BIO). He received a B.B.A. in marketing and finance and his MBA from the University of New Brunswick.